

## **Appendix A (Diabetes and Heart Failure)**

McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. *Lancet Diabetes Endocrinol.* 2014;2:843-51.

Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. *Circulation.* 2001;103:2668-73.

Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, Coresh J. HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. *Diabetologia.* 2008;51:2197-204.

Riehle C, Abel ED. Insulin signaling and heart failure. *Circ Res.* 2016;118:1151-69.

Hölscher ME, Bode C, Bugger H. Diabetic cardiomyopathy: does the type of diabetes matter? *Int J Mol Sci.* 2016 Dec 18;17(12). pii: E2136. doi: 10.3390/ijms17122136.

Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. *Nat Rev Endocrinol.* 2016;12:144-53.

Elder DH, Singh JS, Levin D, Donnelly LA, Choy AM, George J, Struthers AD, Doney AS, Lang CC. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. *Eur J Heart Fail.* 2016;18:94-102.

## **Appendix B (Effects of Insulin on Heart, Blood Vessels and Kidneys)**

Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu M, Waagstein F, Holmäng A. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. *Am J Physiol Heart Circ Physiol.* 2006;291:H787-96.

Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh GY, Akazawa H, Shiojima I, Kahn CR, Abel ED, Komuro I. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. *J Clin Invest.* 2010;120:1506-14.

Arabacilar P, Marber M. The case for inhibiting p38 mitogen-activated protein kinase in heart failure. *Front Pharmacol.* 2015;6:102. doi: 10.3389/fphar.2015.00102.

- Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. *J Clin Invest.* 1999;104:447-57.
- Li Q, Park K, Li C, Rask-Madsen C, Mima A, Qi W, Mizutani K, Huang P, King GL. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C- $\beta$  isoform in the endothelium. *Circ Res.* 2013;113:418-27.
- Park K, Li Q, Rask-Madsen C, Mima A, Mizutani K, Winnay J, Maeda Y, D'Aquino K, White MF, Feener EP, King GL. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. *Mol Cell Biol.* 2013;33:3227-41.
- Isenović ER, Kedees MH, Tepavcević S, Milosavljević T, Korićanac G, Trpković A, Marche P. Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation. *Cardiovasc Hematol Disord Drug Targets.* 2009;9:172-80.
- Stenvinkel P, Ottosson-Seeberger A, Alvestrand A, Bolinder J. Effect of insulin on renal sodium handling and renal haemodynamics in insulin-de-pendent (type 1) diabetes mellitus patients. *Acta Diabetol.* 1995;32:230-4.
- Manhiani MM, Cormican MT, Brands MW. Chronic sodium-retaining action of insulin in diabetic dogs. *Am J Physiol Renal Physiol.* 2011;300:F957-65.
- Stenvinkel P, Bolinder J, Alvestrand A. Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. *Diabetologia.* 1992;35:1042-8.
- Tallam LS, Jandhyala BS. Influence of plasma insulin levels on antinatriuretic and vasoconstrictor actions of angiotensin-II. *Clin Exp Hypertens.* 2003;25:257-70.
- Trevisan R, Fioretto P, Semplicini A, Opocher G, Mantero F, Rocco S, Remuzzi G, Morocutti A, Zanette G, Donadon V, et al. Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. *Diabetes.* 1990;39:289-98.
- Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. *Am J Physiol Renal Physiol.* 2007;293:F974-84.

## **Appendix C (Effect of Insulin on Adipose Tissue)**

- Klemm DJ, Leitner JW, Watson P, Nesterova A, Reusch JE, Goalstone ML, Draznin B. Insulin-induced adipocyte differentiation. Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation. *J Biol Chem.* 2001;276:28430-5.
- Sorisky A. From preadipocyte to adipocyte: differentiation-directed signals of insulin from the cell surface to the nucleus. *Crit Rev Clin Lab Sci.* 1999;36:1-34.
- Kang J, Kim YC, Park JJ, Kim S, Kang SH, Cho YJ, Yoon YE, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ. Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with high-intensity statins. *Cardiovasc Diabetol.* 2018 Jan 11;17(1):10. doi: 10.1186/s12933-017-0650-3.
- Christensen RH, von Scholten BJ, Hansen CS, Heywood SE, Rosenmeier JB, Andersen UB, Hovind P, Reinhard H, Parving HH, Pedersen BK, Jørgensen ME, Jacobsen PK, Rossing P. Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. *Eur J Prev Cardiol.* 2017;24:1517-1524.
- Song DK, Hong YS, Lee H, Oh JY, Sung YA, Kim Y. Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity. *Diabetes Metab J.* 2015;39:405-13.
- Akbas EM, Hamur H, Demirtas L, Bakirci EM, Ozcicek A, Ozcicek F, Kuyrukluıldiz U, Turkmen K. Predictors of epicardial adipose tissue in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr.* 2014 May 9;6:55. doi: 10.1186/1758-5996-6-55.
- Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. *Nat Rev Endocrinol.* 2015;11:363-71.
- Greulich S, Maxhera B, Vandenplas G, de Wiza DH, Smiris K, Mueller H, Heinrichs J, Blumensatt M, Cuvelier C, Akhyari P, Ruige JB, Ouwens DM, Eckel J. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. *Circulation.* 2012;126:2324-34.
- Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. *Circulation.* 2003;108:2460-6.

- Chen WJ, Danad I, Raijmakers PG, Halbmeijer R, Harms HJ, Lammertsma AA, van Rossum AC, Diamant M, Knaapen P. Effect of type 2 diabetes mellitus on epicardial adipose tissue volume and coronary vasomotor function. *Am J Cardiol.* 2014;113:90-7.
- Bambace C, Sepe A, Zoico E, Telesca M, Olioso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M. Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. *Heart Vessels.* 2014;29:42-8.
- Cieslik KA, Trial J, Carlson S, Taffet GE, Entman ML. Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. *FASEB J.* 2013;27:1761-71.
- Cieslik KA, Trial J, Entman ML. Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway. *Am J Pathol.* 2011;179:1792-806.
- Tokudome T, Horio T, Yoshihara F, Suga S, Kawano Y, Kohno M, Kangawa K. Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. *Metabolism.* 2004;53:710-5.
- Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. *Circulation.* 2017;136:6-19.
- Packer M. The leptin-aldosterone-nephrilysin axis: identification of its role in the pathogenesis of the three phenotypes of heart failure in obese people. *Circulation* (in press)
- Altara R, Giordano M, Nordén ES, et al. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. *Front Endocrinol (Lausanne).* 2017 Jul 17;8:160. doi: 10.3389/fendo.2017.00160.

#### **Appendix D (Differences in Heart Failure in Type 1 and Type 2 Diabetes)**

- Konduracka E, Cieslik G, Galicka-Latala D, Rostoff P, Pietrucha A, Latacz P, Gajos G, Malecki MT, Nessler J. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. *Acta Diabetol.* 2013;50:597-606.
- Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. *Dis Model Mech.* 2009;2:454-66.

Park CW, Kim HW, Lim JH, Yoo KD, Chung S, Shin SJ, Chung HW, Lee SJ, Chae CB, Kim YS, Chang YS. Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. *Diabetes*. 2009;58:2666-76.

Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, Yun UJ, McQueen AP, Wayment B, Litwin SE, Abel ED. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. *Diabetes*. 2008;57:2924-32.

LaRocca TJ, Fabris F, Chen J, Benhayon D, Zhang S, McCollum L, Schecter AD, Cheung JY, Sobie EA, Hajjar RJ, Lebeche D. Na<sup>+</sup>/Ca<sup>2+</sup> exchanger-1 protects against systolic failure in the Akitains2 model of diabetic cardiomyopathy via a CXCR4/NF-κB pathway. *Am J Physiol Heart Circ Physiol*. 2012;303:H353-67.

### **Appendix E (Importance of Hyperinsulinemia)**

Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. *Diabetologia*. 2012;55:2946-53.

Erqou S, Lee CT, Suffoletto M, Echouffo-Tcheugui JB, de Boer RA, van Melle JP, Adler AI. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. *Eur J Heart Fail*. 2013;15:185-93.

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405-12.

### **Appendix F (Antihyperglycemic Drugs That May Benefit Heart Failure)**

Packer M. Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes. *Diabetes Care*. 2018;41:11-13.

Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, Omiya H, Ubukata M, Sakai S, Samukawa Y. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. *Eur J Endocrinol*. 2008;158:35-46.

- Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. *Diabetes Obes Metab.* 2015;17:800-4.
- Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *BMJ.* 2009;339:b4731. doi: 10.1136/bmj.b4731.
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998;352:854–865.
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373:2117-28.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017;377:644-657.
- Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, Walser M, Samà M, Aimaretti G, Isgaard J, Saccà L. Metformin prevents the development of chronic heart failure in the SHHF rat model. *Diabetes.* 2012;61:944-53.
- Mayer P, Haas B, Celner J, Enzmann H, Pfeifer A. Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. *Diabetes Obes Metab.* 2011;13:791-9.
- Qi T, Chen Y, Li H, Pei Y, Woo SL, Guo X, Zhao J, Qian X, Awika J, Huo Y, Wu C. A role for PFKFB3/iPFK2 in metformin suppression of adipocyte inflammatory responses. *J Mol Endocrinol.* 2017;59:49-59.
- Li A, Zhang S, Li J, Liu K, Huang F, Liu B. Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice. *Mol Cell Endocrinol.* 2016;434:36-47.

Zulian A, Canello R, Girola A, Gilardini L, Alberti L, Croci M, Micheletto G, Danelli P, Invitti C. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. *Obes Facts*. 2011;4:27-33.

Yagi S, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D, Salim HM, Maimaituxun G, Nishio S, Takagawa Y, Hama S, Matsuura T, Yamaguchi K, Tobiume T, Soeki T, Wakatsuki T, Aihara KI, Akaike M, Shimabukuro M, Sata M. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr*. 2017 Oct 4;9:78. doi: 10.1186/s13098-017-0275-4.

Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. *Cardiovasc Diabetol*. 2017 Mar 3;16(1):32. doi: 10.1186/s12933-017-0516-8.

Díaz-Rodríguez E, Agra RM, Fernández ÁL, Adrio B, García-Caballero T, González-Juanatey JR, Eiras S. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. *Cardiovasc Res*. 2018;114:336-346.

Jing Y, Wu F, Li D, Yang L, Li Q, Li R. Metformin improves obesity-associated inflammation by altering macrophages polarization. *Mol Cell Endocrinol*. 2018;461:256-264.

Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. *JAMA Cardiol*. 2017;2:1025-1029.

### **Appendix G (Antihyperglycemic Drugs That May Worsen Heart Failure)**

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. *N Engl J Med*. 2007;357:28-38.

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). *Diabetes Care*. 2007;30:2773-8.

- Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA*. 2016;316:500-8.
- Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. *Eur J Heart Fail*. 2017;19:69-77.
- Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators. Heart Failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation*. 2015 Oct 13;132(15):e198. doi: 10.1161/CIR.0000000000000330.
- US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication - risk of heart failure. April 5, 2016. Available at: <https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494252.htm>
- Roumie CL, Min JY, D'Agostino McGowan L, Presley C, Grijalva CG, Hackstadt AJ, Hung AM, Greevy RA, Elasy T, Griffin MR. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. *J Am Heart Assoc*. 2017 Apr 19;6(4). pii: e005379. doi: 10.1161/JAHA.116.005379.
- Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. *BMC Cardiovasc Disord*. 2014 Sep 26;14:129. doi: 10.1186/1471-2261-14-129.
- Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. *Circ Res*. 2008;102:164-76.



- Packer M. Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial. *Eur J Heart Fail.* 2018;20:49-51.
- Packer M. Is the way to someone's heart through their stomach? The cardiorenal paradox of incretin-based hypoglycemic drugs in heart failure. *Circ Heart Fail* 2017 Oct;10(10). pii: e004551. doi: 10.1161/CIRCHEARTFAILURE.117.004551.
- Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, Kos K. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. *Clin Sci (Lond).* 2017;131:343-353.
- Mulvihill EE, Varin EM, Ussher JR, et al. Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. *Diabetes.* 2016;65:742-54.
- Packer M. Do dipeptidyl peptidase-4 inhibitors cause heart failure events by promoting adrenergically-mediated cardiotoxicity? Clues from laboratory models and clinical trials. *Circ Res.* 2018 Feb 7. pii: CIRCRESAHA.118.312673. doi: 10.1161/CIRCRESAHA.118.312673.
- Packer M. Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications. *JACC Heart Fail.* 2018 Mar 1. pii: S2213-1779(18)30041-6. doi: 10.1016/j.jchf.2017.12.016.
- Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, Wolford D, Samaha J. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. *Diabetes Care.* 2011;34:730-3.
- Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, Ronzaud C, Hummler E, Vallon V. PPAR $\gamma$  agonist-induced fluid retention depends on  $\alpha$ ENaC expression in connecting tubules. *Nephron.* 2015;129:68-74.
- Chraïbi A, Renauld S. PPAR $\gamma$ -induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent. *Cell Physiol Biochem.* 2014;33:581-93.
- Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. *Pharmacoepidemiol Drug Saf.* 2008;17:769-81.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. *Circulation*. 2003;108:2941-8.

Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. 2015;3:356-66.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367:319-28.

McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H; VIVID Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. *JACC Heart Fail*. 2018;6:8-17.

### **Appendix H (Intensive Glycemic Control and Enhanced Risk of Death)**

Packer M. Increased mortality in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycemic control. *Diabetes Obes Metab*. 2018 Feb 22. doi: 10.1111/dom.13265.

Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. *Am Heart J* 2006;151:91.

Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. *J Am Coll Cardiol* 2009;54:422–428.

Núñez J, Bonanad C, Navarro JP, Bondanza L, Artero A, Ventura S, Núñez E, Miñana G, Sanchis J, Real J. Differential effect of glycosylated hemoglobin value and antidiabetic treatment on the risk of 30-day readmission following a hospitalization for acute heart failure. *Rev Esp Cardiol (Engl Ed)*. 2015;68:852-60.

- Lawson CA, Jones PW, Teece L, Dunbar SB, Seferovic PM, Khunti K, Mamas M, Kadam UT. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. *JACC Heart Fail.* 2017 Oct 4. pii: S2213-1779(17)30605-4. doi: 10.1016/j.jchf.2017.08.020. [Epub ahead of print]
- Grembowski D, Ralston JD, Anderson ML. Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with diabetes: a retrospective 9-year cohort study. *Diabetes Res Clin Pract.* 2014;106:373-82.
- Engoren M, Schwann TA, Arslanian-Engoren C, Maile M, Habib RH. U-shape association between hemoglobin A1c and late mortality in patients with heart failure after cardiac surgery. *Am J Cardiol.* 2013;111:1209-13.
- Shah RV, Altman RK, Park MY, Zilinski J, Leyton-Mange J, Orencole M, Picard MH, Barrett CD, Heist EK, Upadhyay G, Das R, Singh JP, Das S. Usefulness of hemoglobin A(1c) to predict outcome after cardiac resynchronization therapy in patients with diabetes mellitus and heart failure. *Am J Cardiol.* 2012;110:683-8.
- Tomova GS, Nimbale V, Horwich TB. Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus. *Am J Cardiol.* 2012;109:1767-73.
- Nasir S, Aguilar D. Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement. *Am J Cardiol.* 2012;110(9 Suppl):50B-57B.